BioSpace News Archive

Seeking to address estimates that more than a third of COVID-19 deaths nationally have occurred in nursing homes and long-term care facilities—more than 38,000 – the American Medical Directors Association published recommendations for reducing the spread of the pandemic virus among residents and staff.

Rapid improvements have been seen in acutely ill patients with COVID-19 treated with the cancer drug acalabrutinib (Calquence) by researchers, including physicians within The US Oncology Network (The Network).

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, June 8, 2020 at 8:30 am Eastern Time (ET), it will host a webcast and conference call to present new data from the ongoing study of SRP-9003, an investigational gene therapy to treat Limb-girdle muscular dystrophy Type 2E, or beta-sarcoglycanopathy. Results will include expression and safety results from the hi

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it intends to convene and immediately adjourn its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) scheduled to be held on June 11, 2020 at 9:00 a.m., EDT to June 30, 2020 at 9:00 a.m., EDT, and that the adjourned meeting will be cond

BridgeBio Pharma, Inc. announced that on June 1, 2020, the compensation committee of BridgeBio’s board of directors granted nine employees options to purchase an aggregate of 55,517 shares of the Company’s common stock with a per share exercise price of $28.88 and restricted stock units for an aggregate of 19,532 shares of the Company’s common stock, including 607 performance-related restricted stock units.

BOMA New York, REBNY, 32BJ SEIU, Realty Advisory Board on Labor Relations, Inc., Local 94 International Union of Operating Engineers, and AFL-CIO issued New York City’s most comprehensive guidelines to facilitate the safe and healthy reentry into commercial office buildings.

CymaBay Therapeutics, Inc. (Nasdaq: CBAY), today announced that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others,

Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel wound care and biosurgical devices, announces that it has raised $1.4M from long-term shareholders.

Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) is pleased to announce the Company will host a Corporate Update Conference Call and Webcast on June 10th, 2020 at 9 am MT/11 am ET.

Transparency Market Research has published a new report on the acute agitation and aggression treatment market for the forecast period of 2019–2027.